Closing expected in 1H2026 subject to completion of the separation of SpinCo from Avidity and other customary closing conditions "Avidity has expanded the possibilities of what RNA therapeutics can ...
SAN DIEGO and HERCULES, Calif., Feb. 8, 2023 /PRNewswire/ -- Element Biosciences, Inc. — the developer of an innovative DNA sequencing platform disrupting genomics — and Bio-Rad Laboratories, Inc.
Element Biosciences, the developer of the AVITI benchtop sequencer, will be sharing details about its technology and discussing customer stories at the annual meeting of the American Society of Human ...
VENLO, Netherlands, and SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Element Biosciences, Inc. today announced a strategic partnership to offer ...
While next generation sequencing (NGS) has become a staple method for some researchers, it is often out of reach due to its high cost and technical challenges. To solve this problem, a novel ...
SAN DIEGO, Sept. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its early-stage precision cardiology programs into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback